ReviewFrontiers in immunology2026
Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a common chronic inflammatory skin disorder frequently accompanied by multisystem involvement, with increasing concern regarding its association with renal impairment. The advent and widespread use of biologic agents in the treatment of moderate to severe psoriasis have transformed therapeutic strategies, yet their effects on renal function and the underlying mechanisms remain a critical area of investigation. This review synthesizes current clinical and experimental evidence on the renal impact of biologics used in psoriasis management, focusing on the safety profiles of different biologic classes and their roles in modulating kidney-related complications. We explore how immune regulation, inflammation suppression, and cell death pathways contribute to both renal protection and injury, highlighting the influence of tumor necrosis factor (TNF)-α inhibitors, interleukin (IL) -17 and IL-12/23 inhibitors. By integrating recent clinical studies and basic research findings, this article aims to provide clinicians with a theoretical basis for the rational selection of biologic therapies in psoriasis patients with renal concerns and to stimulate further research into optimizing treatment strategies that safeguard kidney health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.